PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor

Prostate

Volumn 66, Issue 12, 2006, Pages 1329-1338

  Litvinov, Ivan V ^a,b   Antony, Lizamma ^a   Dalrymple, Susan L ^a   Becker, Robyn ^a   Cheng, Linzhao ^b   Isaacs, John T ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen receptor; p21; Prostate cancer; Tumor suppressor gene

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CELL PROTEIN; PROTEIN P21; PROTEIN P27; PROTEIN P45SKP2; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; P27 ANTIGEN; S PHASE KINASE ASSOCIATED PROTEIN; TUMOR SUPPRESSOR PROTEIN;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; REGULATORY SEQUENCE; TRANSACTIVATION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETIC TRANSDUCTION; GENETICS; LENTIVIRINAE; MALE; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROMOTER REGION; PROSTATE TUMOR; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; VIROLOGY;

ANIMALS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE EXPRESSION REGULATION, VIRAL; GENES, TUMOR SUPPRESSOR; HUMANS; LENTIVIRUS; MALE; MICE; PROLIFERATING CELL NUCLEAR ANTIGEN; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; S-PHASE KINASE-ASSOCIATED PROTEINS; TRANSDUCTION, GENETIC; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33748369142     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20483     Document Type: Article

References (51)

1. Huss WJ, Gray DR, Greenberg NM, Mohler JL, Smith GJ. Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells. Cancer Res 2005;65(15):6640-6650.
2. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004;117(Pt 16):3539-3545.
3. Litvinov IV, De Marzo AM, Isaacs JT. Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 2003;88(7):2972-2982.
4. Burger PE, Xiong X, Coetzee S, Salm SN, Moscatelli D, Goto K, Wilson EL. Sca-1 expression identifies stem cells in the proximal region of prostatic ducts with high capacity to reconstitute prostatic tissue. Proc Natl Acad Sci USA 2005;102(20):7180-7185.
5. Xin L, Lawson DA, Witte ON. The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci USA 2005;102(19):6942-6947.
6. Uzgare AR, Xu Y, Isaacs JT. In vitro culturing and characteristics of transit amplifying epithelial cells from human prostate tissue. J Cell Biochem 2004;91(1):196-205.
7. Gao J, Arnold JT, Isaacs JT. Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res 2001;61(13):5038-5044.
8. Kurita T, Wang YZ, Donjacour AA, Zhao C, Lydon JP, O'Malley BW, Isaacs JT, Dahiya R, Cunha GR. Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. Cell Death Differ 2001;8(2):192-200.
9. Litvinov IV, Chang C, Isaacs JT. Molecular characterization of the commonly used human androgen receptor expression vector, pSG5-AR. Prostate 2004;58(4):319-324.
10. Rossi R, Zatelli MC, Franceschetti P, Maestri I, Magri E, Aguiari G, Cavazzini P, degli Uberti EC, del Senno L. Inhibitory effect of dihydrotestosterone on human thyroid cell growth. J Endocrinol 1996;151(2):185-194.
11. Rossi R, Zatelli MC, Valentini A, Cavazzini P, Fallo F, del Senno L, degli Uberti EC. Evidence for androgen receptor gene expression and growth inhibitory effect of dihydrotestosterone on human adrenocortical cells. J Endocrinol 1998;159(3):373-380.
12. Lu S, Liu M, Epner DE, Tsai SY, Tsai MJ. Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. Mol Endocrinol 1999;13(3):376-384.
13. Lu S, Jenster G, Epner DE. Androgen induction of cyclin-dependent kinase inhibitor p21 gene: Role of androgen receptor and transcription factor Sp1 complex. Mol Endocrinol 2000;14(5):753-760.
14. Roy-Burman P, Tindall DJ, Robins DM, Greenberg NM, Hendrix MJ, Mohla S, Getzenberg RH, Isaacs JT, Pienta KJ. Androgens and prostate cancer: Are the descriptors valid? Cancer Biol Ther 2005;4(1):4-5.
15. Liao X, Tang S, Thrasher JB, Griebling TL, Li B. Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol Cancer Ther 2005;4(4):505-515.
16. Yang Q, Fung KM, Day WV, Kropp BP, Lin HK. Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival. Cancer Cell Int 2005;5(1):8.
17. Haag P, Bektic J, Bartsch G, Klocker H, Eder IE. Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol 2005;96(3-4):251-258.
18. Kuratsukuri K, Sugimura K, Harimoto K, Kawashima H, Kishimoto T. "Decoy" of androgen-responsive element induces apoptosis in LNCaP cells. Prostate 1999;41(2):121-126.
19. Wright ME, Tsai MJ, Aebersold R. Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol Endocrinol 2003;17(9):1726-1737.
20. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 2002;62(4):1008-1013.
21. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25(2):276-308.
22. Isaacs JT, Isaacs WB. Androgen receptor outwits prostate cancer drugs. Nat Med 2004;10(1):26-27.
23. So A, Gleave M, Hurtado-Col A, Nelson C. Mechanisms of the development of androgen independence in prostate cancer. World J Urol 2005;23(1):1-9.
24. Chlenski A, Nakashiro K, Ketels KV, Korovaitseva GI, Oyasu R. Androgen receptor expression in androgen-independent prostate cancer cell lines. Prostate 2001;47(1):66-75.
25. Tilley WD, Bentel JM, Aspinall JO, Hall RE, Horsfall DJ. Evidence for a novel mechanism of androgen resistance in the human prostate cancer cell line, PC-3. Steroids 1995;60(1):180-186.
26. Yuan S, Trachtenberg J, Mills GB, Brown TJ, Xu F, Keating A. Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. Cancer Res 1993;53(6):1304-1311.
27. Heisler LE, Evangelou A, Lew AM, Trachtenberg J, Elsholtz HP, Brown TJ. Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor. Mol Cell Endocrinol 1997;126(1):59-73.
28. Marcelli M, Haidacher SJ, Plymate SR, Birnbaum RS. Altered growth and insulin-like growth factor-binding protein-3 production in PC3 prostate carcinoma cells stably transfected with a constitutively active androgen receptor complementary deoxyribonucleic acid. Endocrinology 1995;136(3):1040- 1048.
29. Faber PW, van Rooij HC, van der Korput HA, Baarends WM, Brinkmann AO, Grootegoed JA, Trapman J. Characterization of the human androgen receptor transcription unit. J Biol Chem 1991;266(17):10743-10749.
30. Grossmann ME, Lindzey J, Blok L, Perry JE, Kumar MV, Tindall DJ. The mouse androgen receptor gene contains a second functional promoter which is regulated by dihydrotestosterone. Biochemistry 1994;33(48):14594-14600.
31. Lindzey J, Grossmann M, Kumar MV, Tindall DJ. Regulation of the 5′-flanking region of the mouse androgen receptor gene by cAMP and androgen. Mol Endocrinol 1993;7(12):1530-1540.
32. Mizokami A, Chang C. Induction of translation by the 5′- untranslated region of human androgen receptor mRNA. J Biol Chem 1994;269(41):25655-25659.
33. Yeap BB, Voon DC, Vivian JP, McCulloch RK, Thomson AM, Giles KM, Czyzyk-Krzeska MF, Furneaux H, Wilce MC, Wilce JA, Leedman PJ. Novel binding of HuR and poly(C)-binding protein to a conserved UC-rich motif within the 3′-untranslated region of the androgen receptor messenger RNA. J Biol Chem 2002;277(30):27183-27192.
34. Litvinov IV, Antony L, Dalrymple S, De Marzo AM, Drake CG, Isaacs JT. Does Androgen receptor Acquire DNA Replication Licensing Ability in Prostate Cancer Cells?" PNAS 2006; In Press.
35. Litvinov FV, Antony L, Isaacs JT. Molecular characterization of an improved vector for evaluation of the tumor suppressor versus oncogene abilities of the androgen receptor. Prostate 2004;61(4):299-304.
36. Yu X, Zhan X, D'Costa J, Tanavde VM, Ye Z, Peng T, Malehorn MT, Yang X, Civin CI, Cheng L. Lentiviral vectors with two independent internal promoters transfer high-level expression of multiple transgenes to human hematopoietic stem-progenitor cells. Mol Ther 2003;7(6):827-838.
37. Buchschacher GL Jr. Introduction to retroviruses and retroviral vectors. Somat Cell Mol Genet 2001;26(1-6):1-11.
38. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 1978;21(3):274-281.
39. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43(4):1809-1818.
40. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979;17(1):16-23.
41. Sramkoski RM, Pretlow TG II, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D, Jacobberger JW. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 1999;35(7):403-409.
42. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999;5(3):280-285.
43. Jallepalli PV, Waizenegger IC, Bunz F, Langer S, Speicher MR, Peters JM, Kinzler KW, Vogelstein B, Lengauer C. Securin is required for chromosomal stability in human cells. Cell 2001;105(4):445-457.
44. Dalrymple S, Antony L, Xu Y, Uzgare AR, Arnold JT, Savaugeot J, Sokoll LJ, De Marzo AM, Isaacs JT. Role of notch-1 and E-cadherin in the differential response to calcium in culturing normal versus malignant prostate cells. Cancer Res 2005;65(20):9269-9279.
45. Uzgare AR, Isaacs JT. Enhanced redundancy in Akt and mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells. Cancer Res 2004;64(17):6190-6199.
46. Doering CH, Leyra PT. Methyltrienolone (R1881) is not aromatized by placental microsomes or rat hypothalamic homogenates. J Steroid Biochem 1984;20(5):1157-1162.
47. Deslypere JP, Young M, Wilson JD, McPhaul MJ. Testosterone and 5 alpha-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Mol Cell Endocrinol 1992;88(1-3):15-22.
48. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10(1):33-39.
49. Bilodeau M, Talarmin H, Ilyin G, Rescan C, Glaise D, Cariou S, Loyer P, Guguen-Guillouzo C, Baffet G. Skp2 induction and phosphorylation is associated with the late G1 phase of proliferating rat hepatocytes. FEBS Lett 1999;452(3):247-253.
50. Sutterluty H, Chatelain E, Marti A, Wirbelauer C, Senften M, Muller U, Krek W. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol 1999;1(4):207-214.
51. Wirbelauer C, Sutterluty H, Blondel M, Gstaiger M, Peter M, Reymond F, Krek W. The F-box protein Skp2 is a ubiquitylation target of a Cull-based core ubiquitin ligase complex: Evidence for a role of Cull in the suppression of Skp2 expression in quiescent fibroblasts. Embo J 2000;19(20):5362-5375.